Results 81 to 90 of about 1,470 (198)

Impact of Prior Intravenous Immunoglobulin and Plasmapheresis on Eculizumab or Ravulizumab Treatment for Generalized Myasthenia Gravis: An Analysis of the MG SPOTLIGHT Registry

Clinical and Experimental Neuroimmunology, Volume 17, Issue 1, February 2026.
ABSTRACT Objective The complement component 5 inhibitor therapies (C5ITs) eculizumab and ravulizumab are approved for the treatment of generalized myasthenia gravis (gMG). We evaluated the real‐world effectiveness and safety of eculizumab and ravulizumab in patients with gMG with or without prior intravenous immunoglobulin (IVIg) or plasma exchange ...
Akiyuki Uzawa, Ema Rodrigues, Hiroyuki Murai   +2 more
wiley   +1 more source

Bullous pemphigoid – what makes the blister? [PDF]

My thesis focuses on a rare skin autoimmune disease called bullous pemphigoid (BP). It is a disease characterised by itching, nonspecific changes on the skin and tense blisters.
Kotnik, Nika
core   +2 more sources

1‐Year Clinical Outcome Post‐Myasthenic Crisis: A Multicenter Prospective Study in China

European Journal of Neurology, Volume 33, Issue 2, February 2026.
In this prospective cohort of 282 patients with myasthenic crisis (MC) episodes, all‐cause mortality was 15.16%. Among 247 patients who have completed 1‐year follow‐up, 79.76% achieved favorable outcomes with significant improvement in the MG‐activities of daily living (MG‐ADL) score.
Xiao Huan, Ran Chen, Lei Jin, Yuan Wang, Yafang Xu, Lei Yang, Caihua Xi, Jianming Zheng, Lijun Luo, Song Yang, Jianquan Shi, Yanping Liu, Zhe Ruan, Wanlong Wu, Wei Li, Yaoxian Yue, Yarong Li, Wenji Jia, Huahua Zhong, Chong Yan, Jie Song, Jianying Xi, Song Tan, Qilong Jiang, Zhangyu Zou, Chongbo Zhao, Sushan Luo, on behalf of the Chinese Myasthenia Gravis Collaborating Group (CMGCG), Yuzhou Guan, Yuwei Da, Huan Yang, Ting Chang, Yuge Wang, Bitao Bu, Hongyu Zhou, Chunsheng Yang, Hua Zhang, Hui Deng, Ruisheng Duan   +38 more
wiley   +1 more source

A real-world pharmacovigilance study of efgartigimod alfa in the FDA adverse event reporting system database

Frontiers in Pharmacology
ObjectiveEfgartigimod alfa, approved for treating generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive, has uncertain long-term safety in large populations This study analyzed adverse events ...
Yunlin Yang, Jinfeng Liu, Wei Wei, Wei Wei, Wei Wei   +4 more
doaj   +1 more source

Autoimmune Neuromuscular Disorders: Emerging Insights and Future Frontiers [PDF]

: In recent years, our knowledge rapidly increased with respect to the immunology and immunological aspects of neuromuscular disorders [...]
Brighina, Filippo, Di Stefano, Vincenzo
core   +1 more source

Fast-acting treatment of myasthenic crisis with efgartigimod from the perspective of the neuro intensive care unit

BMC Neurology
Background Myasthenic crisis (MC) refers to rapid deterioration of myasthenia gravis (MG), affecting lung and bulbar muscles and causing breathing difficulties.
Fangyi Shi, Rong Lai, Li Feng, Hongyan Zhou, Xunsha Sun, Cunzhou Shen, Jiezhen Feng, Zhilong Xu, Haiyan Wang, Huiyu Feng   +9 more
doaj   +1 more source

Humoral immune response to polyvalent pneumococcal vaccine in healthy participants receiving efgartigimod: a randomized, open-label, placebo-controlled, parallel-group phase 1 trial

Frontiers in Immunology
Background/objectiveEfgartigimod, a human immunoglobulin G1 (IgG1) antibody Fc fragment, reduces IgG levels through neonatal Fc receptor (FcRn) blockade.
Antoine E. Azar, John W. Sleasman, Sophie Steeland, Fien M. Verhamme, Kevin L. Winthrop   +4 more
doaj   +1 more source

Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series

Frontiers in Immunology
IntroductionEfgartigimod is effective and well-tolerated in patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (MG).
Jie Song, Haiyan Wang, Xiao Huan, Qilong Jiang, Zongtai Wu, Chong Yan, Jianying Xi, Chongbo Zhao, Huiyu Feng, Sushan Luo   +9 more
doaj   +1 more source

[Horizon Scanning Of Therapeutic Alternatives For Generalized Myasthenia Gravis And Five-Year Healthcare Expenditure Forecast Model] [PDF]

OBJECTIVE: The objective of the analysis was to assess and quantify the economic impact of generalized Myasthenia Gravis (gMG) in Italy over the next five years (2025—2029) using Horizon Scanning and expenditure forecasting methodologies.METHODS: The ...
Adami, Silvia, Alboni, Paolo Emilio, Bitonti, Rossella, Colalillo, Emanuele, Cristinziano, Adriano, La Seta, Concetta, Marinozzi, Andrea   +6 more
core   +2 more sources

Treating myasthenia gravis beyond the eye clinic [PDF]

Myasthenia gravis (MG) is one of the most well characterised autoimmune disorders affecting the neuromuscular junction with autoantibodies targeting the acetylcholine receptor (AChR) complex.
Jacob, Saiju
core   +1 more source